4568.T Stock - Daiichi Sankyo Company, Limited
Unlock GoAI Insights for 4568.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.89T | $1.60T | $1.28T | $1.04T | $962.52B |
| Gross Profit | $1.47T | $1.19T | $914.95B | $691.56B | $624.23B |
| Gross Margin | 78.0% | 74.1% | 71.6% | 66.2% | 64.9% |
| Operating Income | $303.29B | $184.20B | $102.16B | $146.05B | $127.59B |
| Net Income | $295.76B | $200.73B | $109.19B | $66.97B | $75.96B |
| Net Margin | 15.7% | 12.5% | 8.5% | 6.4% | 7.9% |
| EPS | $155.96 | $104.69 | $56.96 | $34.94 | $39.17 |
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Visit WebsiteEarnings History & Surprises
4568.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 23, 2026 | — | — | — | — |
Q1 2026 | Jan 29, 2026 | — | — | — | — |
Q4 2025 | Oct 29, 2025 | $46.73 | $25.56 | -45.3% | ✗ MISS |
Q3 2025 | Jul 29, 2025 | $35.06 | $47.18 | +34.6% | ✓ BEAT |
Q2 2025 | Apr 23, 2025 | $18.62 | $44.31 | +138.0% | ✓ BEAT |
Q1 2025 | Jan 29, 2025 | $32.52 | $32.32 | -0.6% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $26.40 | $32.23 | +22.1% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $23.30 | $44.60 | +91.4% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $7.56 | $19.38 | +156.3% | ✓ BEAT |
Q1 2024 | Jan 31, 2024 | $16.98 | $34.69 | +104.3% | ✓ BEAT |
Q4 2023 | Oct 31, 2023 | $20.25 | $20.86 | +3.0% | ✓ BEAT |
Q3 2023 | Jul 31, 2023 | $17.06 | $29.74 | +74.3% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $0.90 | $11.73 | +1203.3% | ✓ BEAT |
Q1 2023 | Jan 31, 2023 | $19.83 | $14.81 | -25.3% | ✗ MISS |
Q4 2022 | Oct 31, 2022 | $13.97 | $20.58 | +47.3% | ✓ BEAT |
Q3 2022 | Jul 29, 2022 | $12.66 | $9.84 | -22.3% | ✗ MISS |
Q2 2022 | Apr 27, 2022 | $-7.89 | $-14.27 | -80.9% | ✗ MISS |
Q1 2022 | Jan 31, 2022 | $8.73 | $16.62 | +90.4% | ✓ BEAT |
Q4 2021 | Oct 29, 2021 | $10.76 | $14.22 | +32.2% | ✓ BEAT |
Q3 2021 | Jul 30, 2021 | $11.77 | $18.38 | +56.2% | ✓ BEAT |
Latest News
Frequently Asked Questions about 4568.T
What is 4568.T's current stock price?
What is the analyst price target for 4568.T?
What sector is Daiichi Sankyo Company, Limited in?
What is 4568.T's market cap?
Does 4568.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 4568.T for comparison